Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06457997 · ClinicalTrials.gov registry record · Phase 1
A Study of PHN-010 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Pheon Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT06457997: Clinical Trial Phase 1 study, sponsored by Pheon Therapeutics.
NCT06457997 is a Phase 1 study that was terminated before completion, run by Pheon Therapeutics. The registered enrollment target is 26 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06457997, a Phase 1 study, was terminated before completion, sponsored by Pheon Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Interventions
- DRUG PHN-010
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2025-09-11 |
| Phase | Phase 1 |
Why NCT06457997 stopped before completion
NCT06457997 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 1 intervention - of which PHN-010 is the first listed.
NCT06457997 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06457997 about?
NCT06457997 is a clinical study titled "A Study of PHN-010 in Patients With Advanced Solid Tumors". This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
What is the current status of trial NCT06457997?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2024-07-01. Estimated completion is 2025-09-11.
What interventions are being tested in trial NCT06457997?
The interventions under investigation include: PHN-010 (DRUG).
Who is sponsoring clinical trial NCT06457997?
This trial is sponsored by Pheon Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06457997's enrollment target sits among peer trials
26 1482nd of 2000 higher than 506 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI